Infliximab concentration monitoring improves the control of disease activity in XXXX .

@entity1 @entity9485 @entity309
INTRODUCTION: Adjustment of infliximab dosage for individuals may be useful in improving therapeutic response in @entity309 ( @entity309 ). Herein, we aimed to determine whether measurement of infliximab serum concentration modifies the therapeutic decision and improves the control of disease activity. METHODS: @entity309 @entity1 routinely treated with infliximab were included in an observational open-label study. On visit 1 (V1), according to the disease activity, a preliminary therapeutic decision was selected among four therapeutic options and a blood sample was collected to measure trough serum infliximab concentration. The final therapeutic decision, based on both disease activity and serum infliximab concentration assessed @entity9485 , was applied at the following infusion (V2). Clinical and biological evaluations were performed at V3 and V4 and compared with those @entity9485 . RESULTS: We included 24 @entity1 . The final therapeutic decision differed from the preliminary decision for 12 @entity1 (50%). For @entity1 with increased infliximab dosage @entity9485 , mean disease activity score for 28 joints (DAS28) decreased by about 20% at V3 or V4 as compared with V1 (P < 0.05). Decreased DAS28 was correlated with increased serum infliximab concentration (P < 0.02). CONCLUSIONS: The measurement of infliximab trough concentration modifies the therapeutic decision for @entity309 @entity1 and helps improve control of disease activity. Therapeutic drug monitoring of infliximab in @entity309 may be useful for individual dosage adjustment.
